Lynk Pharmaceuticals Co Ltd, a clinical-stage innovative drug development company focused on autoimmune and inflammatory diseases, announced on Tuesday that its partner, Formation Bio, has dosed the first participant in a Phase 1, first-in-human clinical trial (BLKR201-101-HV) evaluating BLKR201 (originally designated as LNK01006).

The study is a single ascending dose (SAD) and multiple ascending dose (MAD) trial conducted in healthy volunteers, with data readout expected in early 2027.

BLKR201 / LNK01006 is a novel, selective CNS-penetrant allosteric TYK2 inhibitor designed to regulate immune signalling within the central nervous system. TYK2 is a validated target, and the CNS exposure and high target selectivity of this compound may open up opportunities in a range of neural, autoimmune, and inflammatory conditions. This compound incorporates a highly optimised scaffold engineered for target selectivity, metabolic stability, and CNS penetration.

In December 2025, Lynk Pharmaceuticals entered into an exclusive development and licensing agreement with Formation Bio's subsidiary Bleecker Bio for LNK01006 outside Greater China. Under the terms of the agreement, Lynk Pharmaceuticals received a minority equity stake in Bleecker Bio, an upfront payment, and is eligible for additional development, regulatory, and commercial milestones totalling up to USD605m, plus tiered royalties on potential future sales.